Brian Inouye, MD
Urology · Albany, NYNPI 1467871178
Payments from drug & device makers
What this record shows
This record is dominated by grants: $52,000 of the $56,966 with a category attached, or 91.3%. Boston Scientific accounts for 93.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $50,000 and has fallen 89.0% since, to $5,519 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $890.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$53K
- Uromedica, Incorporated$2K
- Laborie Medical Technologies Corp.$923
- Coloplast$369
- Johnson & Johnson$210
- Astellas Pharma US Inc$200
- plus $280 from 8 others
What the payments were for
- Consulting fees$8001%
- Grants$52,00091%
- Travel & lodging$1,5263%
- Food & beverage$2,4414%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 35 | $53,458 |
| Uromedica, Incorporated | 1 | $1,526 |
| Laborie Medical Technologies Corp. | 3 | $923 |
| Coloplast | 10 | $369 |
| Johnson & Johnson | 4 | $210 |
| Astellas Pharma US Inc | 2 | $200 |
| Baxter Healthcare | 1 | $108 |
| Rochester Medical Corporation | 2 | $46 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $31 |
| 180 Medical, Inc. | 1 | $25 |
| Rigicon,inc. | 1 | $23 |
| Pfizer | 1 | $17 |
| BD | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$52,000
- ProACT$1,526
- AMS 700$388
- TITAN$130
- GENERAL PAIN MANAGEMENT$124
- RYBREVANT$123
- CARVYKTI$123
- PerClot$108
- Optilume BPH Drug Coated Balloon Catheter$104
How this compares
$56,966 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 79 | $70,307 |
| GemtesaVibegron | 16 | $15,797 |
| Trospium Chloride ErTrospium Chloride | 12 | $1,476 |
| Tamsulosin Hcl | 85 | $1,003 |
| Finasteride | 62 | $929 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 18 | $731 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $590 |
| Cephalexin | 18 | $325 |
| Clobetasol Propionate | 11 | $279 |
| Levofloxacin | 16 | $118 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $200 | $70,30779 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.
Other urology in Albany
- Ronald KaufmanAlbany$173K
- Brian MurrayAlbany$130K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.